ArticlePLoS pathogens2026
Acetylation enables a dual-targeting fungal effector to inhibit insect immunity and development.
Article in PLoS pathogens, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pathogenic microbes deploy secreted effectors to subvert host immunity and physiology across kingdom boundaries, yet the molecular mechanisms that maintain effector competence during this transition remain poorly defined. Here, we identify MrNIS1, an effector from the insect-pathogenic fungus Metarhizium robertsii whose stability and secretion are governed by K24 acetylation through physical association with the acetyltransferase MrKAT1 and the deacetylase MrSIR2. Once inside the insect, MrNIS1 acts as a dual-targeting effector to disrupt distinct physiological pathways. It binds the serine protease SPS to block prophenoloxidase activation, thereby suppressing melanization-based immunity. MrNIS1 interacts with the evolutionarily conserved cholesterol transporter ERP, disrupting ecdysteroid biosynthesis and leading to impaired larval growth and cuticle synthesis. This MrNIS1-ERP interaction is functionally conserved across Lepidoptera, Coleoptera, and Diptera. Furthermore, heterologous expression in Beauveria bassiana demonstrates that the KAT1/SIR2 regulatory system is conserved across fungal species, where MrNIS1 acts as a portable virulence module to significantly enhance pathogen efficacy. Our findings reveal that lysine acetylation serves as a molecular switch that preserves effector competence during cross-kingdom transit, enabling the simultaneous targeting of multiple host physiological processes. These results elucidate a conserved strategy of fungal pathogenesis and identify potential targets for the improvement of microbial biocontrol agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.